Metabolic profiling identifies lung tumor responsiveness to erlotinib

Teresa W.M. Fan, Andrew N. Lane, Richard M. Higashi, Michael Bousamra, Goetz Kloecker, Donald M. Miller

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.

Original languageEnglish
Pages (from-to)83-86
Number of pages4
JournalExperimental and Molecular Pathology
Issue number1
StatePublished - Aug 2009

Bibliographical note

Funding Information:
This study was supported by NIH Grant Number RR018733 from the National Center for Research Resources, National Science Foundation EPSCoR grant # EPS-0447479, NCI 1R01CA118434-01, the KY Lung Cancer Research Program, Kentucky Challenge for Excellence, and the Brown Foundation. We thank Ms. Lynn Deleeuw and Ms. Vennila Arumugum for sample processing.


  • Bronchioalveolar adenocarcinoma
  • Erlotinib
  • Metabolomics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry


Dive into the research topics of 'Metabolic profiling identifies lung tumor responsiveness to erlotinib'. Together they form a unique fingerprint.

Cite this